Pensioenfonds Rail & OV Acquires 23,222 Shares of Becton, Dickinson and Company $BDX

Pensioenfonds Rail & OV acquired a new position in Becton, Dickinson and Company (NYSE:BDX – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 23,222 shares of the medical instruments supplier’s stock, valued at approximately $4,157,000.

Other institutional investors have also recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in shares of Becton, Dickinson and Company during the second quarter worth $3,721,533,000. State Street Corp boosted its holdings in shares of Becton, Dickinson and Company by 8.5% in the 2nd quarter. State Street Corp now owns 15,000,064 shares of the medical instruments supplier’s stock valued at $2,269,960,000 after buying an additional 1,177,256 shares during the period. First Eagle Investment Management LLC boosted its holdings in shares of Becton, Dickinson and Company by 15.8% in the 2nd quarter. First Eagle Investment Management LLC now owns 13,815,335 shares of the medical instruments supplier’s stock valued at $2,090,675,000 after buying an additional 1,887,224 shares during the period. Bank of America Corp DE bought a new stake in shares of Becton, Dickinson and Company during the 2nd quarter valued at about $474,993,000. Finally, Beutel Goodman & Co Ltd. grew its position in shares of Becton, Dickinson and Company by 9.0% during the 3rd quarter. Beutel Goodman & Co Ltd. now owns 1,835,571 shares of the medical instruments supplier’s stock valued at $328,567,000 after buying an additional 150,931 shares during the last quarter. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, CEO Thomas E. Polen, Jr. sold 2,993 shares of the firm’s stock in a transaction that occurred on Thursday, November 5th. The shares were sold at an average price of $210.00, for a total value of $628,530.00. Following the sale, the chief executive officer owned 110,163 shares in the company, valued at approximately $23,134,230. This trade represents a 2.65% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Feld sold 165 shares of Becton, Dickinson and Company stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $188.49, for a total value of $31,100.85. Following the sale, the executive vice president directly owned 19,720 shares in the company, valued at approximately $3,717,022.80. This trade represents a 0.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 3,310 shares of company stock valued at $688,650 over the last three months. 0.40% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Performance

Shares of BDX traded up $2.24 during midday trading on Friday, hitting $217.95. 1,879,889 shares of the stock traded hands, compared to its average volume of 1,936,421. Becton, Dickinson and Company has a 1-year low of $140.11 and a 1-year high of $219.78. The firm has a market capitalization of $60.05 billion, a PE ratio of 52.64, a price-to-earnings-growth ratio of 3.61 and a beta of 0.22. The company has a debt-to-equity ratio of 0.54, a quick ratio of 0.54 and a current ratio of 0.87. The business’s 50 day moving average price is $190.90 and its two-hundred day moving average price is $170.56.

Becton, Dickinson and Company (NYSE:BDX – Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The medical instruments supplier reported $4.15 EPS for the quarter, topping the consensus estimate of $4.07 by $0.08. Becton, Dickinson and Company had a net margin of 5.66% and a return on equity of 14.90%. The business had revenue of $5.27 billion during the quarter, compared to analyst estimates of $5.11 billion. During the same quarter in the prior year, the firm earned $3.96 earnings per share. The company’s quarterly revenue was up 5.4% on a year-over-year basis. Equities research analysts predict that Becton, Dickinson and Company will post 13.21 EPS for the current fiscal year.

Becton, Dickinson and Company declared that its Board of Directors has initiated a share repurchase program on Thursday, November 5th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to repurchase up to 3.6% of its stock through open market purchases. Share repurchase programs are usually an indication that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 31st. Shareholders of record on Thursday, December 10th will be paid a dividend of $1.06 per share. This represents a $4.24 dividend on an annualized basis and a yield of 1.9%. The ex-dividend date of this dividend is Thursday, December 10th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.05. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 101.45%.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on the stock. Wells Fargo & Company increased their price objective on shares of Becton, Dickinson and Company from $161.00 to $170.00 and gave the stock an “equal weight” rating in a research note on Friday, August 7th. Wolfe Research started coverage on Becton, Dickinson and Company in a research note on Tuesday, October 20th. They issued an “outperform” rating for the company. TD Cowen upped their target price on Becton, Dickinson and Company from $163.00 to $182.00 and gave the company a “hold” rating in a report on Wednesday, August 5th. Barclays upped their target price on Becton, Dickinson and Company from $165.00 to $195.00 and gave the company an “underweight” rating in a report on Tuesday, November 10th. Finally, Stifel Nicolaus set a $195.00 price target on Becton, Dickinson and Company in a research report on Friday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $197.47.

Check Out Our Latest Research Report on BDX

Becton, Dickinson and Company Company Profile

(Free Report)

Becton, Dickinson and Company, commonly known as BD, is a global medical technology company that develops and manufactures products used in healthcare, clinical laboratories and life sciences research. Founded in 1897, the company has a long history of producing medical devices and supplies. BD’s products include syringes, needles, infusion systems and medication-management technologies, as well as equipment and supplies for collecting and processing clinical specimens. The company also provides diagnostic systems, laboratory instruments and tools used in areas such as cell analysis and biomedical research.

Featured Articles

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX – Free Report).

Institutional Ownership by Quarter for Becton, Dickinson and Company (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.